These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 32890017)

  • 1. New pharmacologic agents for insomnia and hypersomnia.
    Earl DC; Van Tyle KM
    Curr Opin Pulm Med; 2020 Nov; 26(6):629-633. PubMed ID: 32890017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.
    Matsumura T; Terada J; Yoshimura C; Koshikawa K; Kinoshita T; Yahaba M; Nagashima K; Sakao S; Tatsumi K
    Drug Des Devel Ther; 2019; 13():809-816. PubMed ID: 30880914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of switching to suvorexant for mild primary insomnia when sleepwalking episodes occur during zolpidem treatment.
    Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
    Asian J Psychiatr; 2017 Dec; 30():122-123. PubMed ID: 28898806
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
    Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
    Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
    Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
    [No Abstract]   [Full Text] [Related]  

  • 7. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
    Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
    Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suvorexant (Belsomra) for insomnia.
    Med Lett Drugs Ther; 2015 Mar; 57(1463):29-31. PubMed ID: 25719996
    [No Abstract]   [Full Text] [Related]  

  • 9. Prescription Drugs Used in Insomnia.
    Dujardin S; Pijpers A; Pevernagie D
    Sleep Med Clin; 2020 Jun; 15(2):133-145. PubMed ID: 32386689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea.
    Powell J; Piszczatoski C; Garland S
    Ann Pharmacother; 2020 Oct; 54(10):1016-1020. PubMed ID: 32270686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L; Juday T; Frech F; Atkins N
    J Clin Psychiatry; 2021 Jun; 82():. PubMed ID: 34077032
    [No Abstract]   [Full Text] [Related]  

  • 15. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
    Schweitzer PK; Rosenberg R; Zammit GK; Gotfried M; Chen D; Carter LP; Wang H; Lu Y; Black J; Malhotra A; Strohl KP;
    Am J Respir Crit Care Med; 2019 Jun; 199(11):1421-1431. PubMed ID: 30521757
    [No Abstract]   [Full Text] [Related]  

  • 16. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Krief S; Berrebi-Bertrand I; Nagmar I; Giret M; Belliard S; Perrin D; Uguen M; Robert P; Lecomte JM; Schwartz JC; Finance O; Ligneau X
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
    Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
    McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
    [No Abstract]   [Full Text] [Related]  

  • 19. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
    Berger AA; Sottosanti ER; Winnick A; Keefe J; Gilbert E; Hasoon J; Thase ME; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2022 Feb; 52(1):68-90. PubMed ID: 35342199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.